Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 255

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities

Wright, Thomas C., Cox, J. Thomas, Massad, L. Stewart, Twiggs, Leo B., Wilkinson, Edward J.·2002·Journal of Lower Genital Tract Disease

Abstract

Each year in the United States, approximately 3.3 million Pap tests are interpreted as having some degree of cytological abnormality [1]. Identifying which of these women are at risk for having a clinically significant cervical abnormality, performing a diagnostic evaluation, and treating clinically significant abnormalities once identified presents a serious clinical and public health problem that has been estimated to cost billions of dollars [2]. This challenge is amplified by the fact that Pap tests are obtained in a variety of clinical settings, including school-based health clinics, sexually transmitted disease clinics, family planning clinics and private physician offices, as well as hospitals and emergency rooms. A spectrum of health care providers is responsible for cervical cancer screening in these various settings, and many of these clinicians have little expertise in managing cervical cytological abnormalities. Because of the magnitude of the clinical problem, there is a clear need for comprehensive, evidence-based guidelines for the management of cervical cytological abnormalities and cervical cancer precursors. There are a number of other reasons why new management guidelines are needed. In May 2001, the National Cancer Institute held a consensus workshop to revise the cervical cytological classification system used in the United States, which is now referred to as the 2001 Bethesda System. The 2001 Bethesda System changes the criteria used by cytologists to render an interpretation of atypical squamous cells (ASC), provides new subcategories of ASC, and changes the subcategories of atypical glandular cells (AGC) [3]. The ASC category is the most common cervical cytological abnormality in the United States, and management guidelines need to be revised to incorporate these changes in terminology. Other reasons for developing new management guidelines are a better understanding of the pathogenesis and natural history of human papillomavirus (HPV) and cervical cancer precursors and the availability of data from the large National Cancer Institute's Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesion Study (ALTS) clinical trial [3a]. This $25 million, multisite, randomized clinical trial was designed specifically to address the best management approaches for women with a cytological result of ASC and low-grade squamous intraepithelial lesions (LSIL). The results of this trial need to be incorporated into clinical care of women in the United States. It is also important to recognize that current guidelines were developed before sensitive molecular methods for detecting high-risk types of HPV and liquid-based cytology methods became widely available. There is now compelling data that combining these two new technologies provides an attractive alternative to the more traditional management approaches for certain types of cytological abnormalities [4–6]. As a result, the use of these new technologies is increasing, and clinicians need clear, unbiased guidelines delineating the strengths and weakness of different management approaches and the best use of the new technologies. To develop comprehensive management strategies for women with cytological abnormalities and cervical cancer precursors, the American Society of Colposcopy and Cervical Pathology (ASCCP) sponsored a National Consensus Conference in Bethesda, MD, on September 6–8, 2001. This meeting had representatives from 29 national and international health organizations, professional societies, and federal agencies. Throughout the development of the guidelines, input was obtained from the professional community at large through a novel approach that incorporated Internet-based discussion groups. This report provides a summary of the key recommendations and algorithms for managing women with cytological abnormalities. A description of the evidence supporting the guidelines and the guidelines themselves have previously been published [7]. Comprehensive literature reviews of the evidence base supporting the recommendations will be published by each of the four Consensus Conference working groups [atypical squamous cells (ASC); atypical glandular cells (AGC); low-grade squamous intraepithelial lesion (LSIL); and high-grade squamous intraepithelial lesion (HSIL)] at a later date in the Journal of Lower Genital Tract Disease. In addition, separate 2001 Consensus Guidelines for the Management of Women with Cervical Histological Abnormalities will also be published at a later date. OVERVIEW OF GUIDELINE DEVELOPMENT PROCEDURES ASCCP began developing the 2001 Consensus Guidelines in the fall of 2000. To ensure that the guidelines reflect the needs of the diverse array of health care providers, federal agencies and national and international health organizations involved in the health care of women were invited to participate in the guideline development process. Twenty-nine different agencies and organizations a

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00128360-200204000-00012

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 255

Metadata

Authors
Wright, T. C., Cox, J. T., Massad, L. S., Twiggs, L. B., & Wilkinson, E. J.
Venue
Journal of Lower Genital Tract Disease
Published
2002-04
Volume
6
Issue
2
Pages
127-143
ISSN
1089-2591 (ISSN-L)
OpenAlex
W2082618248
Cited by
255
References
41
FWCI
13.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. https://app.cochat.ai/papers/10.1097/00128360-200204000-00012
The paper
Wright, T. C., Cox, J. T., Massad, L. S., Twiggs, L. B., & Wilkinson, E. J. (2002). 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. Journal of Lower Genital Tract Disease. https://doi.org/10.1097/00128360-200204000-00012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.